aTYR PHARMA INC (ATYR): Submission of Matters to a Vote of Security Holders
aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 16, 2026, aTyr Pharma, Inc. (the “Company”) held its 2026 Special Meeting of Stockholders (the “Special Meeting”). As of September 4, 2026, the record date for the Special Meeting (the “Record Date”), 98,08
How this was made
The 30-second read
Why it matters
The approval may improve market perception and share price stability, but the actual effect depends on subsequent financing and operational milestones.
Market read
Primary corporate action for a micro‑cap biotech; modest trading relevance.
What to watch
Potential dilution from future financing rounds post‑split could offset price benefits.
Background
ATYR Pharma is a small‑cap biotech company listed on the NYSE. The company sought shareholder approval to restructure its capital base via a reverse split.
Ticker impact
ATYR Pharma filed an 8‑K reporting shareholder approval of a reverse stock split ranging from 1‑for‑10 to 1‑for‑50.
likely upward pressure as the market prices in the higher post‑split share price and reduced float.
Reverse splits are typically viewed as a structural improvement for thinly traded micro‑caps, though execution risk remains.
Market effects
May set a precedent for other micro‑cap biotech firms considering reverse splits to boost share price.
Limited to U.S. biotech micro‑cap segment.
Minimal global impact.
Counterpoint
Reverse splits can signal underlying weakness; investors may stay cautious.
Key entities
- ExecutiveBrandon Yaras
Chief Financial Officer of ATYR Pharma who signed the 8‑K filing.